No Data
Express News | Autolus Therapeutics PLC : Truist Securities Cuts Target Price to $10 From $11
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Announces Target Price $10
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Autolus Therapeutics: Positive Momentum Amid Financial Challenges
Express News | Wells Fargo & Co has downgraded the target price for Autolus Therapeutics from $8 per share to $6. The company is a biopharmaceutical firm that develops next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases.